尿路上皮癌に対するM-VAC化学療法における全身投与と動注投与の副作用の比較

Abstract

WBC, Hbのnadirの値やnadirまでの期間に差はなく, 腎機能, 食欲不振の期間においても差は認めなかった.血小板のnadirの平均値は全身投与の方が低かったが, nadirになるまでの期間は動注投与の方が早かった.動注特有の副作用として, 局所の皮膚障害や, 神経障害が認められた

We retrospectively studied the toxic effects in 14 patients with urothelial cancer who had undergone intra-arterial M-VAC chemotherapy (Group A) and 13 patients who had received intravenous M-VAC chemotherapy (Group V) between February 1991 and August 1995. No statistically significant differences were found in the white blood cell count nadir, liver function, renal function or appetite between the groups. While the platelet count nadir for intra-arterial infusion (14.0 x 10(4)/mm3) was larger than for intravenous infusion (9.0 x 10(4)), the median days to nadir for this count was shorter in the intra-arterial group (9.1 days) than in the intravenous group (13.5). In addition, the difference between the beginning hemoglobin level and the nadir level was larger in the intra-arterial infusion group (2.55 g/dl) than in the intravenous infusion group (1.95 g/dl). Additionally peculiar side effects were noted in the intra-arterial infusion group which included local erythema and nerve paralysis. Side effects should be managed for intra-arterial M-VAC as well as for intravenous infusion.